Impaired methylation: what it is, why it matters and what your DNA can reveal

Methylation is a biochemical process in which a small chemical unit (a methyl group) is attached to DNA, proteins, neurotransmitters, or hormones. This process switches genes on or off, regulates mood chemistry, supports detoxification, and maintains cardiovascular health, happening billions of times per second across every cell in the body. When the methylation cycle works efficiently, it supports stable energy, clear cognition, effective stress processing, and healthy ageing. When it is impaired, whether from genetic variants, nutritional gaps, or lifestyle factors, the downstream effects can include elevated homocysteine, reduced neurotransmitter availability, impaired detoxification, and accelerated biological ageing. Understanding your own methylation status is one of the most actionable insights available for long-term preventative health.

Impaired methylation does not produce a single recognisable symptom set, which is part of what makes it easy to overlook. Common patterns include persistent fatigue that does not resolve with adequate sleep, low mood or depression, anxiety and difficulty managing stress, brain fog and difficulty concentrating, recurrent mouth ulcers, poor recovery from illness, and elevated homocysteine on a blood test. Some people with impaired methylation also experience cardiovascular symptoms such as elevated blood pressure or early atherosclerosis, which run through the homocysteine pathway. Because these symptoms overlap with many other conditions, identifying impaired methylation typically requires genetic variant analysis and functional blood markers rather than symptoms alone.

MTHFR variants are among the most prevalent functional genetic variants in the population. Approximately 10% of people in the UK carry two copies of the C677T variant (homozygous), which can reduce MTHFR enzyme activity by up to 70%. A larger proportion carry one copy (heterozygous), producing a more modest reduction in efficiency. The A1298C variant is similarly common, and a significant number of people carry combinations of both. Most people with MTHFR variants are unaware they have them. Many experience no measurable effect if their nutritional intake and lifestyle consistently compensate for the reduced enzyme activity, but those whose diet or lifestyle creates additional stress on the cycle are more likely to develop measurable downstream effects.

Homocysteine is an amino acid produced during normal protein metabolism. In a well-functioning methylation cycle, homocysteine is efficiently converted back to methionine (via the MTR enzyme using B12 and folate) or directed into the transsulphuration pathway (via the CBS enzyme using B6). When methylation is impaired, whether from genetic variants or nutrient deficiencies, homocysteine accumulates in the blood. Elevated homocysteine is associated with increased cardiovascular risk, cognitive decline, and inflammation. This is why homocysteine is used as a functional indicator of methylation status: it reflects how well the cycle is actually running in practice, not just what the genes suggest about theoretical capacity.

There is a meaningful body of research linking methylation pathway variants, particularly MTHFR and COMT, to depression, anxiety, and mood regulation. The connection runs through neurotransmitter production: serotonin, dopamine, and norepinephrine are all synthesised and broken down through methylation-dependent pathways. The COMT enzyme, which breaks down dopamine and oestrogen, is heavily dependent on SAM (the methyl donor produced by a functioning methylation cycle). When SAM availability is reduced due to methylation impairment, COMT activity can be altered, shifting the balance of these neurotransmitters. This does not mean methylation impairment causes mood disorders directly, but it can be a contributing factor in people who do not respond fully to standard nutritional or pharmaceutical approaches.

NHS testing does not routinely include MTHFR variant analysis or DNA methylation profiling. Homocysteine testing is occasionally available through NHS blood panels but is not part of standard primary care assessment. For most people, accessing a comprehensive DNA methylation test (covering genetic variants and biological age) requires going through a private testing provider. If a GP suspects methylation dysfunction based on elevated homocysteine or a family history of cardiovascular disease or thrombosis, they may consider requesting MTHFR testing via a reference laboratory, though this is not standard practice in most UK primary care settings.

A standard MTHFR test checks for two specific gene variants (C677T and A1298C) and returns a result indicating how many copies of each you carry. A broader DNA methylation test analyses methylation patterns across thousands of sites on the genome, generating information about biological age, gene expression regulation, and how the methylation machinery is functioning across multiple pathways simultaneously. Stride's approach combines both layers: genetic variant analysis of the key methylation pathway genes (MTHFR, COMT, MTR, MTRR, CBS) alongside epigenetic biological age data derived from genome-wide DNA methylation patterns. This gives a genetic foundation and a functional readout in a single test.

For people with confirmed MTHFR C677T (homozygous or compound heterozygous), the most evidence-supported nutritional adjustment is replacing standard folic acid with methylfolate (5-MTHF), which does not require MTHFR enzyme conversion. Methylcobalamin (active B12) is preferred over cyanocobalamin for the same reason. Riboflavin (B2) supports MTHFR enzyme function and is worth considering alongside folate and B12. Betaine (trimethylglycine) provides an alternative methyl donor via the BHMT pathway, reducing dependence on the MTHFR-dependent route. These are supportive nutritional inputs, not treatments for any condition. Dosage and suitability should always be discussed with a qualified practitioner based on your specific genetic and blood test results.

For people with mild methylation impairment driven primarily by nutritional gaps rather than significant genetic variants, dietary changes can make a meaningful difference. A consistent supply of active folate (from leafy greens and legumes), B12 (from animal-source foods or supplements), B6 (from poultry, fish, and potatoes), and choline (from eggs and liver) provides the methylation cycle with the raw materials it needs. Betaine from beetroot, spinach, and wholegrains adds a parallel methyl donor. For people with compound genetic variants that significantly reduce enzyme activity, diet alone is less likely to be sufficient. Tracking homocysteine and biological age at intervals is the most reliable way to see whether what you are doing is actually shifting your methylation status for your individual biology.

Biological age, measured through DNA methylation clocks, reflects how the body's epigenetic patterns have shifted relative to chronological age. These clocks work by analysing methylation levels at specific sites across the genome: sites that change in a predictable direction as the body ages, and that are strongly influenced by lifestyle, diet, stress, sleep, and the efficiency of the methylation machinery itself. An elevated biological age (older than chronological age) indicates that the cumulative effect of these factors is accelerating epigenetic drift. Retesting biological age at six-month intervals, alongside making tracked changes to nutrition and lifestyle, allows you to see whether the actions you are taking are measurably slowing or reversing this process for your biology specifically.